AstraZeneca Seeks To Block Actavis' Generic Diabetes Drug
AstraZeneca AB recently filed suit in New Jersey federal court alleging Watson Laboratories Inc. and Actavis Inc.'s attempt to create a generic version of its Onglyza Type 2 diabetes drug infringes...To view the full article, register now.
Already a subscriber? Click here to view full article